在阿尔茨海默病的认知效率的后期评估,使用AMBAR的潜增长混合模型,这是一个2B期随机对照试验
Nicolai D Ayasse1, Walter F Stewart2, Richard B Lipton3
1Department of Patient-Centered Outcomes, Statistics and Psychometrics, OPEN Health, Parsippany, NH, USA (at the time of work being conducted).
Current Alzheimer research
|September 25, 2024
概括
在阿尔茨海默氏症痴呆 (AD) 试验中识别不同的患者群体可以揭示真正的治疗效果. 在AMBAR试验中分析认知轨迹显示,一个稳定的群体从治疗中受益,被可变响应者所掩盖.
科学领域:
- 神经科学是一个神经科学.
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 阿尔茨海默氏症痴呆症 (AD) 的进展涉及各种认知和功能衰退.
- 异质的患者轨迹可以掩盖临床试验中的治疗疗效.
研究的目的:
- 量化未观察到的异质性对AD治疗响应的影响.
- 通过解决患者分层问题,探索改善AD试验中治疗效果检测的方法.
主要方法:
- 潜增长混合模型被用来识别在阿尔茨海默氏症管理通过白蛋白替代 (AMBAR) 2b期试验中不同的认知轨迹.
- 一个2类模型被安装在治疗臂上,然后应用于模拟数据集 (n=1000),代表AMBAR数据.
主要成果:
- 两种患者类别出现了:一种具有稳定的认知能力,另一种具有高度可变的轨迹.
- 排除变量类 (22%的患者) 显示了治疗对认知的显著疗效 (p=0.007,科恩的D=-0.4).
- 模拟表明治疗疗效有利于治疗臂中的稳定子组.
结论:
- 通过分析策略来解决未观察到的患者异质性,可能会提高AD试验中的治疗效果检测.
- 这项研究突出了潜阶级分析在优化AD临床试验设计和解释方面的潜力.
- 模拟建模有助于减轻原始试验中安慰剂组规模较小所带来的局限性.
关键词:
艾姆巴尔 (Ambar) 是一个名为"艾姆巴尔" (Ambar) 的女性.阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.潜增长混合模型的模型.认知 认知 认知探索性分析. 探索性分析.交换等离子体交换等离子体交换没有观察到的异质性.更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.8K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.5K
相关概念视频
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:26Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451